GC Pharma said it obtained marketing approval for Rozetelpine, a four-drug combination treatment for hypertension/hyperlipidemia.

Rozetelpine combines hypertension medicines telmisartan and amlodipine with hyperlipidemia drugs rosuvastatin and ezetimibe.

GC Pharma confirmed Rozetelpine’s efficacy in a phase 3 trial in about 130 Korean patients who had high blood pressure and excessive lipids in the blood.

The study results showed that Rozetelpine effectively lowered the mean sitting systolic blood pressure (msSBP) and LDL-C, known as “bad” cholesterol, in the treatment group, compared with the control group.

The latest approval allows GC Pharma to simultaneously provide various treatment options – from monotherapy to two-drug, three-drug, and four-drug combo – for patients suffering from hypertension and hyperlipidemia.

As over 50 percent of hypertension patients accompany hyperlipidemia and find it inconvenient to take medicines for each disease, commercialization of the four-drug combo treatment is likely to help improve patients’ quality of life, the company said.

“Taking one pill that contains four different ingredients will improve patients’ quality of life,” an official at GC Pharma said. “Just as we proved the drug’s effect in the clinical trial, the drug will make it more convenient for patients to get treatment.”

GC Pharma’s metabolic syndrome treatments include hyperlipidemia drugs David, Azetduo; hypertension drugs Neo Cande, Candedipine; hypertension/hyperlipidemia two-drug combo Rotacand, three-drug combo Rozetel, and four-drug combo Rozetelpine.